FDA approves Glaxo cancer drug Votrient

WASHINGTON (Reuters) – U.S. regulators gave the nod to GlaxoSmithKline Plc’s Votrient for a type of sarcoma on Thursday, following a positive advisory panel vote last month.

Leave a Reply

Read the original at Reuters: Science News.